What can we learn from early stage IO trials?
The search continues to find novel IO approaches to be used either with or instead of checkpoint blockade in a number of advanced solid tumours.
Plain sailing or a rocky road ahead?
In the recent past, much of the combination strategies tended to focus almost exclusively on the adaptive immune system with limited results given the majority of people still do not respond to these therapies.
What if we could utilise the innate immune system in a complementary fashion much more effectively than we have previously?
In order to achieve this nirvana, we need to develop either new technologies to facilitate jumpstarting the stalled immune system or think creatively about doublet and triplet regimens which make sense in tackling the different immune defects present.
Here’s a look at two such early approaches where we explore the latest data and put it context of both what’s known, and also where we’re likely headed…
BSB subscribers can read up on our ongoing commentary and analysis from the cancer conference season – you can either log-in or click to access our latest analysis.
This content is restricted to subscribers
